^
Association details:
| Biomarker: | SMO mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5253 - SMO as a predicted biomarker on immunotherapy and correlated with immune infiltrates in mCRC
Published date:
03/09/2022
Excerpt:
7.3% (8/109) patients in the clinical cohort harbored SMO mutation. Survival analysis in the public cohort demonstrated that SMO mutation resulted in significantly longer OS (10.5 vs 8 months; HR, 0; p=0.035) in mCRC patients treated with ICIs.
